Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib

This is a multicentre single-arm prospective phase II trial evaluating pirtobrutinib in the treatment of relapsed/refractory (R/R) Chronic Lymphocytic Leukaemia (CLL) patients who have previously received zanubrutinib, and to specifically evaluate Bruton Tyrosine Kinase (BTK) mutational status (clonal dynamics) before, during and after treatment with pirtobrutinib.

Trial Details

NCT ID
NCT06812715
Phase
PHASE2
Sponsor
Peter MacCallum Cancer Centre, Australia
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Pirtobrutinib
Locations (sample)
  • Melbourne, Victoria, Australia|-37.814,144.96332
  • Melbourne, Victoria, Australia|-37.814,144.96332
  • Melbourne, Victoria, Australia|-37.814,144.96332

Key Eligibility Criteria

  • Patient has provided written informed consent using the PIPOZA Patient Information and Consent Form (PICF)
  • Confirmed diagnosis of CLL according to iwCLL 2018 criteria, also including CLL with atypical immunophenotype
  • Prior systemic therapy, which must include zanubrutinib as the most recent prior line of therapy. Patients must have received at least one cycle (2…
  • Patients must have an indication for second- or subsequent-line treatment in the opinion of the investigator as defined by iwCLL 2018 criteria, inc…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →